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ABSTRACT: Diclofenac is one of the most widely prescribed nonsteroidal
anti-inflammatory drugs worldwide. It is frequently detected in surface
waters; however, whether this pharmaceutical poses a risk to aquatic
organisms is debated. Here we quantified the uptake of diclofenac by the
fathead minnow (Pimephales promelas) following aqueous exposure (0.2−
25.0 μg L−1) for 21 days, and evaluated the tissue and biomolecular
responses in the kidney. Diclofenac accumulated in a concentration- and
time-dependent manner in the plasma of exposed fish. The highest plasma
concentration observed (for fish exposed to 25 μg L−1 diclofenac) was
within the therapeutic range for humans. There was a strong positive
correlation between exposure concentration and the number of developing
nephrons observed in the posterior kidney. Diclofenac was not found to
modulate the expression of genes in the kidney associated with its primary
mode of action in mammals (prostaglandin-endoperoxide synthases) but
modulated genes associated with kidney repair and regeneration. There were no significant adverse effects following 21 days
exposure to concentrations typical of surface waters. The combination of diclofenac’s uptake potential, effects on kidney
nephrons and relatively small safety margin for some surface waters may warrant a longer term chronic health effects analysis for
diclofenac in fish.
■ INTRODUCTION
Diclofenac is one of the most widely prescribed nonsteroidal
anti-inflammatory drugs (NSAID) worldwide.1 It is used to
treat a wide variety of pain and inflammatory disorders.
Globally, approximately 1000 tons of diclofenac are consumed
annually.2 Diclofenac has a favorable safety profile in humans,
but has nevertheless been associated with occasional
hepatotoxicity, gastrointestinal and adverse renal effects.3
Concerns regarding possible adverse environmental effects of
diclofenac first arose more than a decade ago when reports
implicated the veterinary use of diclofenac in the poisoning and
decline of Asian vulture populations.4 Consumption of
diclofenac-treated livestock carcasses by the vultures has
subsequently been proven to induce renal damage (arising as
a consequence of altered renal blood flow and a buildup of uric
acid) and visceral gout. This has resulted in Gyps vulture
population declines of >95%, including localized extinctions,
and at least one Gyps species is now critically endangered as a
consequence.5−8 The adverse effects of diclofenac on Gyps
vultures are still a major international concern.9,10
Diclofenac is present in wastewater treatment plant (WwTP)
effluents (where it has been measured to reach up to 5.45 μg
L−1)11−16 and in the wider aquatic environment, including
rivers and estuaries (up to 1.2 μg L−1).13,17,18 Diclofenac has
also been measured in groundwater (9.7−477 ng L−1)19−21 and
in some drinking water sources (2.5−35 ng L−1).22,23 The
removal of diclofenac at WwTPs is variable and depends on the
treatment system. Poor adsorption of diclofenac to activated
sludge and resistance to biodegradation means its removal rate
is generally low (measured at between 21 and 40%)2,24−26 and
this, together with evidence for adverse effects on renal function
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in vultures, highlights the potential of this pharmaceutical for
impacting aquatic life.
Standardized ecotoxicity tests report acute EC50 values for
diclofenac at between 15 and 68 mg L−1 and between 23 and
72 mg L−1 for algae and daphnia, respectively.27−29 In juvenile
medaka (Oryzias latipes) the 96 h lethal concentration (LC)10 is
reported at 8 mg L−1.30 No observed effect concentrations
(NOECs) have been reported at 10 mg L−1 in algae, 1 mg L−1
in daphnia, 12.5 mg L−1 in rotifers, and 4 mg L−1 in fish
embryos (for growth, reproduction, embryo and larvae
mortality, respectively)31 suggesting diclofenac is unlikely to
adversely affect these aquatic organisms at concentrations with
environmental relevance.
The end points of standardized toxicity tests, however, do
not necessarily capture the mode of action for diclofenac and
possible effects on the kidney. Some studies in fish have
suggested that chronic diclofenac exposure can cause effects at
lower concentrations than those established as safe by acute or
subchronic toxicity testing. Histopathological effects have been
reported in the kidney, liver and gill of diclofenac exposed fish,
including in rainbow trout (Oncorhynchus mykiss) and brown
trout (Salmo trutta) at the relatively low concentrations of 1 to
5 μg L−1.32−35 In contrast, in a study by Memmert et al.36 in
rainbow trout, an effect on the gills, specifically on the presence
and incidence of interlamellar chloride cells, thickened lamellar
tips, and mononuclear cell foci, was seen only at 1000 μg L−1
diclofenac. These different reported effect concentration
thresholds prompted a review of selected histopathological
findings37 and based on the authors’ interpretive assessments,
they suggested an overall effective NOEC for histopathological
effects of 320 μg L−1. Diclofenac exposure in fish has also been
shown to induce changes in the expression of a variety of genes;
related to prostaglandin synthesis (its primary pharmacological
mode of action)32 as well as genotoxicity,30 inflammation, and
the immune response,38,39 at exposure concentrations in the
low μg L−1 range.
The question of whether diclofenac, at concentrations
detected in European surface waters, has the potential to
exert adverse effects in fish is still unclear. This is an especially
important question given that diclofenac is now included by the
European Commission on a watch-list of pharmaceutical
substances for targeted EU-wide monitoring.40 The possible
regulation of diclofenac and associated potential restrictions
would have wide ranging and economic implications for a
number of stakeholders, including for the human and
environmental health, and water treatment service sectors. It
is important therefore, that there are sufficient high quality data
available on the effects of exposure of aquatic organisms to
diclofenac to allow for an accurate environmental risk
assessment to be made.
Here we investigated uptake following waterborne exposure
to diclofenac and responses in the kidney of fathead minnow
(Pimephales promelas), a fish species widely used in interna-
tional regulatory guidelines for chemical testing. We hypothe-
sized that diclofenac exposure would result in altered pathology
in the kidney and we investigated this through assessing
molecular and histological changes in the kidney of fish exposed
to a range of diclofenac concentrations, including concen-
trations that have been measured in the environment.
■ MATERIALS AND METHODS
Chemicals. All chemicals and reagents were obtained from
Sigma-Aldrich (Dorset, UK) unless otherwise stated.
Fish Maintenance. Fathead minnows were obtained from
breeding populations sourced from U.S. EPA, Duluth,
Minnesota and maintained at Brixham Environmental Labo-
ratory, UK. Their age at the start of the experiment was 11
months. Fish were fed twice daily, with frozen brine shrimp
(Gamma, Tropic Marine Centre, UK) and commercial pellet
(Special Diet Services, Essex, UK) at each feeding. All
husbandry conditions, including photoperiod, light intensity,
water temperature, aeration, aquarium size and source of
aquarium water are detailed in Supporting Information (SI)
Table S1.
Experimental Protocol. Male fathead minnows were
exposed to water containing diclofenac (0, 0.2, 1.0, 5.0, and
25.0 μg L−1; CAS number 15307−79−6) for 21 days via a
continual flow-through system in duplicate tanks. These
concentrations were selected to cover environmentally and
pharmacologically relevant exposures. Water quality parameters
(temperature, dissolved oxygen, pH, conductivity, hardness,
alkalinity, chlorine, and ammonia levels) were monitored
throughout the study, and exposure conditions including
number of animals per aquarium are all detailed in SI Table
S1. All animal procedures were carried out according to UK
Home Office guidelines.
Biological effects assessments were carried out after 48 hours
(h) and 21 days (d) of exposure to diclofenac as described in SI
1.1. Fish were euthanised by immersion in benzocaine, followed
by destruction of the brain, and then sampled for molecular and
histological analysis according to details described in SI 1.1.
Determination of Diclofenac Concentrations in Water
and Plasma. Concentrations of diclofenac in the exposure
water were quantified on exposure days −3, 0, 2, 7, 14, and 21
in all tanks. Diclofenac concentrations in plasma samples were
measured in terminated fish at 48 h and 21 d of exposure.
Detailed methods on the chromatographic separation and mass
spectrometry analysis of diclofenac in the water and plasma are
provided in SI 1.2 and 1.3, respectively. The limit of
quantitation was 0.05 μg L−1 for water and 0.5 μg L−1 for
plasma. In this manuscript we use these measures to calculate
bioconcentration factors (BCFplasma), defined here as the ratio
of the concentration of diclofenac in the fish plasma to the
concentration of diclofenac in the aquarium water at the times
of the sample collections.
Histological Analysis of the Kidney. Fish were fixed in
Bouin’s solution and subsequently decalcified (using 10%
formic acid and 5% formalin) and cut in to 4 mm transverse
sections. Sections were embedded in paraffin wax and
processed for histology according to Paull et al.41 Serial
sections were cut at 4 μm and stained with hematoxylin and
eosin. A detailed description of the histology methods is
provided in SI 1.4.
An average of six slides (minimally three), were assessed per
fish, incorporating sections taken at multiple positions between
the anterior kidney and midway along the longitudinal axis of
the posterior kidney. Numbers of glomeruli, developing
nephrons (DNs) and basophilic cell clusters (BCs) were
counted in the posterior kidney sections, alternating between
the right and left side of the organ. Numbers of DNs and BCs
have been validated as useful biomarkers of nephrotoxicity.42
All measurements were standardized relative to the area of the
transverse kidney cross section analyzed (the number of
glomeruli, DN and BC were expressed per square millimeter,
and criteria for the identification of DN and BC were followed
according to Cormier et al.42). Analysis of the cell types and
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numbers were conducted on slides that were blinded to avoid
possible bias in the assessments. Measurements were taken
using image analysis software (analySIS, version 3.2; Soft
Imaging System, GmHB, Germany).
Statistical Analysis. Data are presented as mean ± SEM.
All statistical analyses were carried out using SigmaStat 3.1
(Systat Software Inc.) unless otherwise stated. Measured
concentrations of diclofenac below the limit of quantitation
in control water were assigned a value of 0 (as no diclofenac
was added to the controls). For plasma samples where
measured concentrations of diclofenac were below the limit
of quantitation, these were assigned a value half the limit of
quantitation for the data analyses, as they could in fact contain a
very low level of diclofenac. Data were assessed for normality
and homogeneity of variances using the Kolmogorov−Smirnov
and Levene’s median tests, respectively. When parametric
assumptions were met, data were analyzed using analysis of
variance (ANOVA) with post hoc assessment of differences
made using the Holm-Sidak multiple comparison method.
Kruskal−Wallis one-way ANOVA was used to compare
medians where normality assumptions were not met and post
hoc Dunn’s multiple comparison procedure applied as
appropriate. A two factor nested ANOVA, with tank as a
random factor, was applied to assess for tank effects in data
analyses. We tested whether the number of basophilic cell
clusters (BCs) and developing nephrons (DNs), and the
number of glomeruli, measured in posterior kidney tissue
increased with the exposure concentration of diclofenac using
Spearman’s rank correlation (using SPSS Statistics, version 22,
IBM). We characterized the statistically significant relationship
between the number of BCs and DNs, and exposure
concentration by fitting a three parameter asymptotic
exponential function by least-squares regression. Data were
considered statistically significant at p < 0.05.
RNA Extraction, Library Preparation, and Sequencing.
RNA was isolated from the anterior kidney of adult male
fathead minnows using Tri Reagent, according to the
manufacturer’s instructions and further purified using RNeasy
MinElute Cleanup with on column DNase treatment (Qiagen
Ltd. West Sussex, UK). RNA quality was assessed on the
Agilent BioAnalyser with RNA 6000 Nano Kit (Agilent
Technologies Ltd. Berkshire, UK) according to the manufac-
turer’s instructions. All RNA used for library construction had
A260/A280 and A260/A230 ratios >1.8 and RIN scores in the range
7.0−9.2. cDNA libraries were prepared using Illumina TruSeq
RNA Sample Preparation Kit and subsequent cluster generation
was conducted using TruSeq Paired-End Cluster Generation kit
(Illumina, San Diego CA).
In total 24 samples were prepared for sequencing: six
replicate samples from each of four treatment groups (0 μg L−1
diclofenac (control) and 25.0 μg L−1 diclofenac, at 48 h and 21
days of exposure). Eight samples were sequenced per lane using
an Illumina GAII platform (76bp paired-end).
Transcriptomic Analysis. Raw reads were quality-
trimmed, clipped and filtered using the FASTX-Toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/). Overlapping reads
were separated from orphan reads and combined into single
extended reads using FLASH.43 A de novo fathead minnow
transcriptome was created from all orphan reads, overlapping
(extended) reads and nonoverlapping reads (forward reads
on l y ) u s i ng the Tr in i t y p l a t f o rm ( t r i n i t y rn a -
seq_r2013_08_14).44
Annotation of the de novo assembled transcripts was carried
out using Trinotate (http://trinotate.sourceforge.net/) and
Blast+.45 Abundance was estimated for all annotated transcripts
using RSEM46 and differential gene expression was analyzed
using EdgeR47 and R/Bioconductor (version 2.2.0)48 using a
selection of scripts provided by Trinity. For each time point (48
h and 21 d), differences in gene expression were determined
between the diclofenac exposed fish and their time-matched
controls. Genes were considered differentially expressed when
the false discovery rate (FDR) < 0.1 (Benjamini-Hochberg
multiple testing correction). Word clouds were generated using
the fold-change values for up- and down-regulated genes using
www.wordle.net. Hierarchical clustering (Ward’s method and
Euclidean distance) was performed on TMM-normalized
FPKM expression values of the differentially expressed genes
(FDR < 0.1) and visualized by creating heatmaps. Functional
annotation analysis was conducted on lists of differentially
expressed genes to identify enriched Gene Ontologies (GO
terms) and/or KEGG pathways using DAVID (v6.7).49 GO
terms and pathways were considered to be enriched when P
values adjusted for multiple-testing <0.1 (Benjamini-Hoch-
berg). Functional enrichments between control (48 h vs 21 d)
and diclofenac (48 h vs 21 d) were visualized using the
Enrichment Map plugin50 for Cytoscape 2.8.351 and the
Functional Annotation Charts produced by DAVID (cutoff
values used for P value, Q value, and overlap coefficient were
0.001, 0.05, and 0.6, respectively). The same methods were
used to perform comparisons between control fish at 48 h and
21 d, and between exposed fish at 48 h and 21 d, to determine
the effect of time on the transcript profile of anterior kidneys
within our experimental system. Full details on the tran-
scriptomic analyses are provided in SI 1.5. All raw sequence
data are accessible at the NCBI Sequence Read Archive through
accession number SRP076715.
■ RESULTS
Water Chemistry. The mean (arithmetic) measured
concentrations of diclofenac were 0.19 ± 0.005 μg L−1
(93.8% of the corresponding nominal concentration), 0.95 ±
0.02 (94.9%), 5.15 ± 0.13 (103.0%), and 23.92 ± 0.31 (95.7%),
for the 0.2, 1.0, 5.0, and 25.0 μg L−1 diclofenac treatment
groups, respectively (SI Table S2). Diclofenac was not detected
in the control treatment group (limit of detection = 0.05 μg
L−1).
Concentrations of Plasma Diclofenac. There were no
differences between replicate tanks within treatment groups
(two factor nested ANOVA, F1,30 = 0.094, p = 0.993).
Following 48 h of exposure, plasma concentrations of
diclofenac were 6.4 ± 1.2, 35.3 ± 7.1, and 205.0 ± 30.5 μg
L−1 for the 1, 5, and 25 μg L−1 treatment groups, respectively.
Diclofenac concentrations in the plasma of the control and 0.2
μg L−1 treatment groups were below the limit of detection (0.5
μg L−1) in all the samples measured (Figure 1). Fish exposed to
diclofenac at 25 μg L−1 for 48 h had significantly higher plasma
concentrations compared with other treatment groups,
including control (two-way ANOVA with Holm-Sidak multiple
comparison procedure, F4,99 = 54.3, p < 0.001).
The calculated ratios between water and plasma concen-
trations (BCFplasma) after 48 h exposure to diclofenac were 6.7
± 1.3, 7.0 ± 1.4, and 8.49 ± 1.3 for the 1, 5, and 25 μg L−1
treatment groups, respectively. There were no significant
differences in the calculated ratios between these treatment
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groups (Kruskal−Wallis one-way ANOVA, H2 = 1.582, p =
0.453; Figure 1).
At 21 d exposure, there were no differences between replicate
tanks within treatment groups (two factor nested ANOVA, F1,59
= 1.475, p = 0.212) and plasma concentrations of diclofenac
had increased significantly to 26.1 ± 3.5, 113.1 ± 18.7, and
510.7 ± 62.1 μg L−1 for the 1, 5, and 25 μg L−1 treatment
groups respectively (two-way ANOVA with Holm-Sidak
multiple comparison procedure, F1,99 = 19.2, p < 0.001; Figure
1). In the lowest diclofenac treatment group (0.2 μg L−1),
concentrations were above the limit of detection in 50% of
samples measured (4.1 ± 1.4 μg L−1). All samples were
measured below the limit of detection in the control treatment
group. There was a statistically significant interaction between
exposure concentration and the day of analysis (F4,99 = 9.7, p <
0.001). At the highest exposure concentration (25 μg L−1), the
average plasma concentration of diclofenac (510.7 μg L−1) had
reached human plasma therapeutic levels (Cmax >420 μg
L−1).52,53
The calculated ratios between water and plasma concen-
trations of diclofenac (BCFplasma) after 21 d exposure were 22.3
± 7.9, 27.4 ± 3.7, 21.9 ± 3.6, and 21.4 ± 2.6 for the 0.2, 1, 5,
and 25 μg L−1 treatment groups, respectively. There was no
significant difference in these ratios between treatment groups
(Kruskal−Wallis one-way ANOVA, H3 = 1.98, p = 0.576;
Figure 1).
Fish Morphometrics. There were no significant differences
in either condition factor (K) or hepatosomatic index (HSI)
between any of the treatment groups after 48 h or 21 d
exposure (K: Kruskal−Wallis one-way ANOVA, H4 = 3.939, p
= 0.414, and H4 = 4.255, p = 0.373, for 48 h and 21 days,
respectively; HSI: one-way ANOVA, F4,78 = 0.466, P = 0.760
for 48 h and Kruskal−Wallis one-way ANOVA, H4 = 1.749, p =
0.782 for 21 d). All associated data (including length and
weight) are presented in SI Table S3.
Histology. Typical histological sections and the structural
features of the posterior kidney in control and diclofenac
exposed fish are shown in Figure 2. There was no evidence of
differences in the morphology of glomeruli, BCs or DNs in any
diclofenac treatment groups compared with controls. However,
the number of BCs and DNs observed in the posterior kidneys
increased with diclofenac concentrations (Spearman rank
correlation, rs = 0.76, n = 10 tanks, p = 0.01; Figure 3). The
relationship was described by number of BCs and DNs = 2.63
(1.97e−1.6 diclofenac [μgL‑1]), R2 = 0.86. We observed increased
cellularity and inflammation of the glomeruli (glomerulitis) and
inflammation of the tubules (nephritis) in the kidneys of fish
exposed to 25 μg L−1 diclofenac (SI Figure S1). Inflammatory
cell infiltrates were predominantly chronic-active in composi-
tion. Associated cells were comprised mainly of mononuclear
lymphocytes and histiocytes, together with a lesser number of
neutrophils and eosinophils. Glomeruli and associated Bow-
man’s capsules were observed along the posterior kidney but
not in the anterior kidney. There was no significant correlation
between the number of glomeruli and diclofenac exposure
concentration (Spearman rank correlation, rs = 0.172, n = 10
tanks, p = 0.634). No abnormal pathologies were observed in
the anterior kidney. This tissue predominantly consisted of
hematopoietic cells, with some steroidogenic and chromaffin
cells located around the blood vessels. Furthermore, no notable
changes were observed in the sinusoidal or vascular profile
structure of either control or diclofenac exposed fish.
Transcriptome Assembly and Annotation. In total,
233 824 042 raw Illumina sequence reads were obtained from
the 24 sample libraries. After preprocessing, 108 659 244
sequence reads were retained and assembled de novo to create
a reference anterior kidney transcriptome. SI Table S4 shows
the number of sequence reads for each sample library before
and after the various processing steps. A total of 144 701
contigs were constructed with sizes ranging from 200 to 14 002
bp (mean contig size of 934 bp) and the transcriptome had an
N50 (the contig length where half of the assembly is
represented by contigs of this size or longer) of 1600. A total
of 66 329 contigs were annotated using a variety of public
sequence databases and peptide/protein predictions (e.g., signal
peptides and protein motifs; see SI 1.5 for further details and SI
Table S5 for the full annotation table, including transcript
sequences).
Effect of Diclofenac Exposure on Gene Expression in
the Anterior Kidney. Analysis of the MDS plot (SI Figure
Figure 1. (A) Plasma concentrations of diclofenac in fish at 48 hours
(h) and 21 days (d) exposure. * denotes significantly different to
control treatment group (Two Way ANOVA with Holm-Sidak
multiple comparison procedure, F4,99 = 54.3, P < 0.001). (B)
Bioconcentration factors (BCF) of diclofenac for blood plasma after
48 h and 21 d exposure. There were no significant differences between
treatment groups measuring above 0 at 48 h (Kruskal−Wallis one-way
ANOVA, H2 = 1.582, p = 0.453) or 21 d exposure (Kruskal−Wallis
one-way ANOVA, H3 = 1.98, p = 0.576). BCF values were 0 for both
the 0 (control) and 0.2 μg L−1 diclofenac treatment groups at 48 h,
and 0 μg L−1 diclofenac (control) treatment group at 21 d.
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S2) showed two control samples (one from 48 h and 21 d
treatment groups respectively) were outliers and these were
subsequently removed from the data set prior to differential
gene expression analysis.
Exposure of fathead minnow to diclofenac for 48 h resulted
in the differential regulation of 74 genes compared to controls,
23 of which were down-regulated and 51 were up-regulated
(FDR < 0.1; Figure 4, SI Table S6). Some of these genes have
previously been shown to be affected by diclofenac and they
include; interleukins,54,55 nitric oxide synthase 2b (nos2b),56
suppressor of cytokine signaling 3b (socs3b),57 c−c motif
chemokines,57 clusterin,58 desmin a (desma), solute carrier
family genes,59 jun B,60 nuclear factor, erythroid 2, and
ectonucleoside triphosphate diphosphohydrolases.61
Functional annotation analysis did not identify enriched gene
ontologies and/or KEGG pathways in the lists of genes
differentially expressed at 48 h diclofenac exposure. There was
no effect of diclofenac treatment on the expression of
prostaglandin-endoperoxide synthase (ptgs) genes in the
anterior kidney. Previously known as cyclooxygenase, these
genes code for enzymes through which the therapeutic effects
of NSAIDs are exerted in mammals. There was however a
group of 13 differentially expressed genes associated with
processes and pathways linked with inflammation (SI Table
S7). A further group of differentially expressed genes were
associated with extracellular matrix and muscle related proteins,
including some genes previously associated with kidney fibrosis.
Most of these 18 differentially expressed genes were up-
regulated (SI Table S8). Other genes differentially expressed at
this time point included some associated with the immune
system (e.g., h2-k1 and Ig mu chain C region membrane
bound), as well as calcium binding and ion transport genes
(e.g., cacna2d4b, efcab1, scn1b, lin7a, atp1b1, and cadpsb).
After 21 d exposure, only 14 genes were found to be
differentially expressed compared with controls; six being
down-regulated and eight up-regulated (Figure 4, SI Table S6).
Of these, cytochrome p450 family 257,62,63 and bax (an
apoptosis regulator)64 have been identified previously to be
affected by diclofenac. Functional annotation analysis did not
identify enriched gene ontologies and/or KEGG pathways in
these differentially expressed genes. Furthermore, there was no
overlap between differentially expressed genes at 48 h and 21 d.
Differential gene expression was also observed for each
treatment group over time: in control samples, comparisons
between the expression profiles of samples analyzed at 48 h
compared to 21 d identified 93 genes differentially expressed
(71 up- and 22 down-regulated), and in the samples from
diclofenac exposed fish, 258 genes were differentially expressed
over time (145 up- and 113 down-regulated) (SI Table S6).
Functional enrichment was found within the groups of genes
that were altered over time within each treatment (SI Table
S9). Some molecular processes were significantly over-
Figure 2. Histopathology of male fathead minnow kidney from control (a−c) and 25 μg L−1 diclofenac exposed fish (d−f) at 21 days, showing
basophilic cell clusters (clusters of small, basophilic, crescent shaped cells) (a and d), further proliferation of basophilic cell clusters to form c-shaped
clusters (b and e) and formation of s-shaped developing nephrons (organized groups of basophilic epithelial cells usually forming a narrow lumen) (c
and f)). Sections are taken from various locations longitudinally along the posterior kidney. Hematoxylin & Eosin stain. Scale bar = 50 μm.
Figure 3. Relationship between diclofenac and the number of
basophilic cell clusters (BCs) and developing nephrons (DNs) per
mm2 in the posterior kidney. The number of BCs and DNs observed
in the posterior kidneys increased with increased diclofenac
concentrations (Spearman rank correlation, rs = 0.76, n = 10 tanks,
p = 0.01). The relationship is described by y = 2.63 (1.97e−1.6x) (R2 =
0.86), where y = number of BCs and DNs and x = diclofenac [μg L−1].
Values shown are mean ± standard error.
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represented (adjusted P values < 0.1) in both control and
diclofenac-exposed fish, including oxygen binding and oxygen
transporter activity. In addition, enriched processes specific for
each of the treatment groups were also observed, including iron
ion binding (controls) and structural constituent of ribosome
and structural molecule activity (diclofenac) (SI Table S9).
■ DISCUSSION
In this study we demonstrated concentration and time
dependent uptake of diclofenac into the plasma of fish
following aqueous exposures. Differentially expressed genes in
the anterior kidney did not include the known primary targets
(e.g., ptgs) through which the therapeutic effects of NSAIDs are
exerted (in mammals) but did include other genes related to
the mode of action of diclofenac at plasma concentrations
equivalent to human therapeutic levels. There was a strong
positive correlation between increasing concentrations of
diclofenac and the number of BCs and DNs observed in the
posterior kidneys, which may be indicative of recovery from
recent kidney damage. The significance of these effects on
kidney function, however, is not known.
Current environmental concentrations of diclofenac (span-
ning between 0.003 and 5 μg L−1) are low compared with
human therapeutic plasma concentrations, which range
between 500 and 3000 μg L−1.52,53 At the highest exposure
concentration in our study (25 μg L−1), the plasma
Figure 4. (A and B) Differentially expressed genes in the anterior kidneys of fathead minnow exposed to diclofenac for 48 h, represented as a word
cloud. Up- and down-regulated genes are represented in green (A) and red (B) respectively, and letter height and shade are proportional to the fold-
change values. (C and D) Heatmap shows differential gene expression in control and diclofenac libraries after 48 h (C) and 21 days (D) of exposure.
The cluster diagrams were created using all differentially expressed genes (adjusted P values <0.01). The level of gene expression is visualized by
using a color gradient from dark green (low expression) to dark red (high expression).
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concentration of diclofenac reached human therapeutic plasma
concentrations and at more environmentally relevant exposure
concentrations (1 and 5 μg L−1; the 95th percentile for
diclofenac in UK WwTP effluents is 0.85 μg L−116 and
measured up to 1.2 μg L−1 for rivers and estuaries
globally13,17,18), plasma diclofenac was 6 and 27% of the
human therapeutic dose, respectively. Fish and other aquatic
organisms may bioconcentrate diclofenac leading to internal
concentrations higher than those in the water. Furthermore, in
fish, as occurs in humans, diclofenac undergoes enterohepatic
cycling, which potentially prolongs its availability within the
organism.65 The average calculated ratios between water and
plasma concentrations (BCFplasma) across treatment groups
after 48 h and 21 d exposure were 7.4 (±0.56) and 23.3 (±1.4),
respectively. The difference between these values is likely
because steady state diclofenac plasma concentrations were not
reached at 48 h exposure. Brown et al.11 report steady state to
occur in rainbow trout plasma after 2 d exposure to diclofenac,
however, Memmert et al.36 suggest that between 10 and 14 d
exposure are required (measured in whole bodies of rainbow
trout). The calculated ratios between water and plasma
concentrations of diclofenac (BCFplasma) in the present study
in fathead minnow are in most cases slightly higher than those
previously reported for diclofenac in rainbow trout (from 2.5 to
29),11,12,38,66 which may indicate species or environmental (e.g.,
temperature) differences in the bioconcentration potential of
diclofenac and/or differences in the metabolism and excretion
dynamics of diclofenac between species. Diclofenac has also
been shown to accumulate in other tissues, including muscle,
kidney, liver, and gill, in the bile, and also in whole
bodies.32,33,36,67
Our global gene expression analysis in the fathead minnow
did not identify any diclofenac induced differential expression
of ptgs (cyclooxygenase) genes in the anterior kidney. The
most widely recognized pharmacological activity of diclofenac
in humans is inhibition of the ptgs enzymes.1 ptgs1 is
constitutively expressed in most tissues and regulates the
synthesis of prostanoids with functions that include cytopro-
tection of the gastric mucosa, regulation of renal blood flow,
and platelet aggregation.68 ptgs2 is mostly inducible, although it
is also constitutively present in the kidney,69 and expression is
greatly increased at inflammatory sites in response to cytokines,
hormones, growth factors and hypoxia. These drug targets are
conserved across vertebrates70 and both ptgs genes have been
characterized in a number of fish species.71−73 Diclofenac (at
concentrations as low as 1 μg L−1) has previously been shown
to reduce the transcription of ptgs1 and ptgs2 in the liver, gills
and kidney of rainbow trout,32 and reduce the synthesis of
prostaglandin E2 in brown trout anterior kidney macrophages
in vitro.35 However, microarray analysis of hepatic gene
expression in rainbow trout found exposure to diclofenac at
concentrations between 11.5 and 81.5 μg L−1 did not alter ptgs
transcription, although a down-regulation was seen at the lower
concentration of 1.6 μg L−1.38 Similarly, in a recent study in
three-spined sticklebacks, exposure to diclofenac at 1 μg L−1
had no effect on the expression of ptgs genes in the gill.74 The
regulation of ptgs is complex, and little is known with respect to
differences in fish species. Furthermore, the prostanoids
produced via the cyclooxygenase pathway have a diverse array
of effects on a variety of cellular processes, and they do not
always act in a similar and coordinated manner.75,76 The
expression of ptgs genes may therefore depend on the net
effects of prostaglandins, their balance or timing of expression
within a tissue or during a physiological response, and this may
account for the variability in expression seen across different
studies.
Over 20% of the genes differentially expressed in response to
diclofenac exposure (at a concentration equivalent to a human
therapeutic level) were associated with inflammation. These
genes included: two members of the interleukin cytokine family
(il11a and il1b, up regulated by 66.5- and 14-fold, respectively),
the latter an important mediator of the inflammatory response
and inducer of ptgs2 expression; hepcidin (hepc1, up-regulated
by 147-fold), important in the maintenance of iron homeostasis
and induced by cytokines during inflammation; nos2b (up-
regulated by 34-fold), induced by pro-inflammatory or
mechanical stresses including tissue injury, and catalyzes the
production of nitric oxide, which is important for cytokine
signaling; GTP cyclohydrolase 1 (gch1, up-regulated by 76-
fold), which transcribes a rate-limiting enzyme in tetrahy-
drobiopterin biosynthesis, an essential cofactor required by
nitric oxide synthases, and also a modulator of inflammatory
pain; and socs3b (up-regulated by 4.7-fold), an inflammatory
regulator that mediates a negative feedback system regulating
cytokine signal transduction via the JAK/STAT pathway.
Although these responding genes appear to be associated
with the established and putative mechanisms of action of
diclofenac, a commonly prescribed anti-inflammatory drug,1 the
lack of significant effects seen on the ptgs genes make it difficult
to draw any specific pathway associations.
In the present study, we observed a concentration-dependent
increase in the number of developing nephrons in the kidney,
and at the highest exposure concentration we found some
evidence of increased cellularity and inflammation of both the
glomeruli and tubules. As for mammalian kidneys, fish kidneys
have the ability to repair after injury, including following
exposure to a variety of toxicants.42,77,78 Additionally, fish are
also able to regenerate kidney nephrons de novo after renal
damage.79−81 Intensely basophilic, compact developing tubules
are occasionally seen in normal adult fish kidneys, but are
increased significantly after nephrotoxicant induced injury,
allowing fish to rapidly regenerate lost nephrons.82 The
presence of increased numbers of new nephrons in adult fish
therefore implies recently induced toxicant damage.42 Studies in
zebrafish suggest this process is reminiscent of nephrogenesis in
mammals and that similar mechanisms govern nephron
formation in both species.83 However, the extent to which
the fish kidney compares with that of higher vertebrates,
including mammals, in terms of toxicant exposure is less well
understood. Evidence from this investigation of nephron
neogenesis in fish following exposure to diclofenac suggests
exposure (to 25 μg L−1 diclofenac) may cause damage to fish
kidneys. We did not see evidence for any obvious kidney
damage, such as tubular necrosis, however such an analysis
would require a more comprehensive, and a time-course
analysis, to effectively capture this information. We also found
that a relatively high proportion (>20%) of differentially
expressed genes following exposure to 25 μg L−1 diclofenac
were associated with extracellular matrix proteins. Extra cellular
matrix has been recognized as having a key influence on organ
formation and repair,84 and many kidney diseases, including
inflammatory processes, are associated with changes in the
expression and distribution of components of extracellular
matrix.85,86 Most of these genes were up-regulated and include:
FAT atypical cadherin 1 ( fat1, up-regulated by 4.8-fold),
involved in controlling cell proliferation during development
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and also a regulator of actin cytoskeletal organization, playing
an important role in actin dynamics and filament rearrangement
characteristic of the kidney’s response to podocyte injury;87
clusterin (clu, up-regulated by 4.6-fold), an extracellular
chaperone that prevents aggregation of non-native proteins
and a regulator of cell proliferation, it has also been shown to
be associated with renal repair and cell proliferation in kidney
tubules88 and its up-regulation during renal injury may act as a
protective response against the development of renal fibrosis;89
two regulators of G protein signaling, including rgs2 (up-
regulated by 8.6-fold), previously shown to negatively regulate
progression of fibrosis in kidneys;90 f ibronectin 1b ( fn1b, up-
regulated by 6.5-fold), a large adhesive glycoprotein involved in
the regulation of cell adhesion, proliferation and differentiation,
and associated with the development of fibrosis;91 and socs3b,
not only a major regulator of inflammation but may also play an
important role in the renal fibrosis repair process, controlling
cellular proliferation and regeneration through HNF-1β
regulation.92 Renal fibrosis is the consequence of an excessive
accumulation of extracellular matrix that occurs in many types
of chronic kidney disease.93 However, we found no evidence of
fibrosis at the tissue level in the histopathology of the anterior
or posterior kidneys. Furthermore, many of these tran-
scriptomic responses were transient and not maintained over
the whole exposure period. The possible health impacts of the
molecular and cellular responses we see in the kidney tissues
are unknown and will also depend on the wider biological costs
of kidney tissue injury and regeneration where it occurs.
We also observed significant changes in the transcriptome
over time, both in the control and to a greater extent in the
diclofenac treatment group. To our knowledge, temporal
changes in transcriptomic data across all treatment groups are
uncommonly reported but important for understanding the
biology of the organism under investigation. The present study
was designed to avoid confounding variability arising from
factors including sex and stage of development, and to maintain
animals in a highly controlled environment. However, fish were
moved from large mixed sex stock tanks into smaller tanks with
males only. There was also a reduction in fish density over the
exposure period due to terminal sampling of a proportion of
fish at 48 h. Such environmental perturbations have the
potential to change the social behaviors of fish, particularly
promoting territoriality and the formation of dominance
hierarchies within groups. These behaviors have been
associated with stress94 and this may have altered levels of
activity within tanks, which in turn may explain the temporal
changes in genes associated with oxygen transport. There were
many more genes differentially expressed over time in the
diclofenac exposed fish compared to control fish, possibly
reflecting differences in the way these fish adjusted to their tank
environment.
Our study has demonstrated that diclofenac can be taken up
by fish and can cause transcriptomic and morphological
alterations in the kidney at plasma concentrations equivalent
to human therapeutic levels. Of particular note is the finding
that exposure to diclofenac can result in abnormal kidney
pathology that might suggest kidney damage as indicated by
nephron neogenesis. However, the consequences of these
alterations on individual health are unknown and further work
is needed to inform on this. Furthermore, these effects were
seen at aqueous exposure concentrations that exceed current
reported concentrations in the environment, although in some
cases by 5-fold only.95,96 Overall, considering current exposure
levels in most ambient aquatic environments, the accumulative
potential, and exposure effects threshold for diclofenac, our
study indicates a low likelihood for significant health impacts to
fish for exposures over a period of a few weeks. However, the
combination of diclofenac’s uptake potential, effects on kidney
nephrons and relatively small safety margin for some surface
waters may warrant a longer term chronic health effects analysis
for diclofenac in fish.
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